TrialSite learned of a temporary halt of vaccinations in Belgium using the Johnson & Johnson (Janssen) COVID-19 vaccine for individuals 41 or under after a person died after receiving the jab. Now the Belgium government approached the European Medicines Agency (EMA) to discuss an investigation prior to the lifting of any regulatory pause. Noting that the actual impact on the overall COVID-19 vaccine drive is de minimis, Belgium has accepted the Johnson & Johnson vaccine on use for elderly with less mobility and the homeless as it only necessitates one jab. They report they’ll continue on with inoculating those cohorts. The incident occurred “where there were serious side effects after administering the Janssen vaccine.”
Thus far, about 80% of 40,000 doses of the Janssen vaccine have been administered thus far to individuals 45 years of age and up. Johnson & Johnson resumed mass vaccination in Europe but added a label after April 20 on the request of countries, including Belgium, to pause the use due to concerns of links to blood clots.
Apparently, a woman under 40 who worked for a company outside of Belgium was given the vaccine outside the Belgian health system...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).